105
Participants
Start Date
December 12, 2022
Primary Completion Date
January 31, 2025
Study Completion Date
September 30, 2026
divozilimab
anti-CD20 monoclonal antibody
"Llc Profimed", Barnaul
"Municipal Autonomous Healthcare Institution of the Order of the Red Banner of Labor City Clinical Hospital No.1", Chelyabinsk
Regional Clinical Hospital No.3, Chelyabinsk
Kuzbass Clinical Hospital named after S.V. Belyaev, Kemerovo
"Khanty-Mansiysk autonomous district - Ugra The district clinical hospital", Khanty-Mansiysk
Center for Cardiology and Neurology, Kirov
Regional Clinical Hospital № 1 named after Professor S. V. Ochapovsky, Krasnodar
Moscow Regional Clinical Research Institute named after M.F. Vladimirsky (MONIKI), Moscow
"LLC Medis", Nizhny Novgorod
Semashko Regional Clinical Hospital, Nizhny Novgorod
State Novosibirsk Regional Clinical Hospital, Novosibirsk
Pyatigorsk City Clinical Hospital No.2, Pyatigorsk
"Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University", Rostov-on-Don
Pavlov First Saint Petersburg State Medical University, Saint Petersburg
Seredavin Regional Clinical Hospital, Samara
Republican Clinical Hospital No.4, Saransk
Siberian State Medical University, Tomsk
"Medical and Sanitary Unit Neftyanik", Tyumen
Ulyanovsk Regional Clinical Hospital, Ulyanovsk
Lead Sponsor
Biocad
INDUSTRY